Experts warn that efforts to mandate reporting of drug company payments to doctors show a lack of transparency, hindering accountability.
Efforts to improve transparency around the payments that drug companies make to doctors, which could influence their practice, have been hit by an "appalling" lack of progress, experts warn.A series of government led workshops on the topic, held between March and July this year, failed to reassure campaigners and researchers that a commitment to mandatory reporting of such payments would be forthcoming, according to attendees who spoke to The BMJ.
No takes yet. Share an insight, caveat, or question.
Chris Baraniuk (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: